Attached files

file filename
EX-17 - Glucose Health, Inc.ex17.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  February 15, 2012
 
 
BIO-SOLUTIONS, CORP.

(Exact Name of Registrant as Specified in Its Charter)


Nevada

(State or Other Jurisdiction of Incorporation)

     
333-113296
 
98-0557171
(Commission File Number)
 
(IRS Employer Identification No.)

14517 Joseph Marc Vermette
Mirabel (Quebec), Canada
J7J 1X2

(Address of Principal Executive Offices)

 
(514)  686-2611

(Registrant’s Telephone Number, Including Area Code)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Forward Looking Statements

           Certain  statements  included  in this Form 8-k regarding  Bio-Solutions, Corp. (the “Company”) that are not  historical  facts are  forward-looking statements,  including  the  information  provided  with  respect  to the future business  operations  and  anticipated  operations  of the Company.    These forward-looking  statements are based on current expectations, estimates,  assumptions and beliefs of management,  and words such as "expects," "anticipates,"   "intends,"   "plans,"   "believes,"   "estimates"  and  similar expressions  are intended to identify  such  forward-looking  statements.  These forward-looking  statements involve risks and uncertainties,  including, but not limited  to,  the  success  of our  current  or  proposed  business  activities.  Accordingly, actual results may differ.


Section 5- Corporate Governance and Management

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

On February 15, 2012  the Company received notice from Mark Solomon that he is resigning from the Board of Directors.  Mr. Solomon  tendered his resignation for personal reasons and there was no disagreement between Mr. Solomon and the Company regarding its business operations or financial reporting.
 
 

Item 9.01 Financial Statements and Exhibits.


Exhibit:  17:  Resignation Letter


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:   February 24, 2012
         
 
Bio-Solutions, Corp.
 
 
 
By:  
/s/Gilles Chaumillon
 
   
Gilles Chaumillon, CEO